Helen Gogas - Concepedia

Author

Helen Gogas

National and Kapodistrian University of Athens ORCID

Also Known As

Gogas H, Gogas H., Gogas, Helen, H Gogas, H. GOGAS, H. Gogas, H. J. Gogas, H.J. Gogas, HELEN GOGAS, Helen Gogas

598

Publications

33.9K

Citations

H-Index

137

Concepts

All Affiliations

National and Kapodistrian University of Athens Laiko General Hospital of Athens Aristotle University of Thessaloniki Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Metropolitan Hospital

About

Helen Gogas is an author at National and Kapodistrian University of Athens specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	47	119	9.8K
2	Health Sciences	14	19	886
3	Public Health	7	7	424
4	Engineering	1	1	927
5	Social Sciences	1	1	16

Helen Gogas

230

Publications

29.4K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation Caroline Robert, Georgina V. Long, Benjamin Brady, New England Journal of Medicine	2014	5.3K
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, New England Journal of Medicine	2017	2.1K
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, New England Journal of Medicine	2014	1.8K
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, The Lancet Versus DabrafenibVal600 Braf-mutant MelanomaOncologyMelanomaPharmacotherapy	2015	1.4K
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma Caroline Robert, Jean‐Jacques Grob, Daniil Stroyakovskiy, New England Journal of Medicine	2019	1.3K
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma David Liu, Bastian Schilling, Derek Liu, Nature Medicine	2019	1K
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial Reinhard Dummer, Paolo A. Ascierto, Helen Gogas, The Lancet Oncology	2018	991
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma Eliezer M. Van Allen, Nikhil Wagle, Antje Sucker, Cancer Discovery EngineeringRaf Kinase InhibitorsPathologyCancer BiologyTumor Biology	2013	927
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma Antoni Ribas, Richard Kefford, Margaret Marshall, Journal of Clinical Oncology	2013	811
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study Georgina V. Long, Keith T. Flaherty, Daniil Stroyakovskiy, Annals of Oncology	2017	640

Page 1